US equities |
TSLA $391.62 ▲+5.21% MU $903.70 ▲+2.98% META $630.56 ▼-1.88% NVDA $216.00 ▲+2.39% AAPL $343.91 ▼-1.10% SPCX $146.90 ▼-0.40% MSFT $532.60 ▲+1.54% AMD $531.28 ▲+2.80%
FinancialContent

Elicio Therapeutics, Inc. - Common Stock (NQ:ELTX)

1.700 -0.200 (-10.53%)
Delayed Quote Updated: 4:00 PM EDT, Oct 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Elicio Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Elicio Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Elicio Therapeutics Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Elicio Therapeutics Reaches Alignment with FDA on ELI-002 Registrational Strategy
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Why INNOVATE Shares Are Trading Higher By Over 19%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Why Versus Systems Shares Are Trading Higher By Around 71%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics Announces Completion of Phase 2 AMPLIFY-7P Study Enrollment
Phase 2 randomized study of ELI-002 enrolled 135 patients; formal interim analysis of disease-free survival (“DFS”) expected in H1 2025 
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer (“SITC”) 2024 Annual Meeting
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation Summit
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics Reports Inducement Grants
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Elicio Therapeutics Reports Inducement Grants
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted, mKRAS-Specific Amphiphile Vaccines
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
ELTX Stock Earnings: Elicio Therapeutics Beats EPS for Q2 2024 ↗
ELTX stock results show that Elicio Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics Announces Closing of Private Placement of $20.0 Million Convertible Note
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Why Is Cancer Vaccine Developer Elicio Therapeutics Stock Trading Lower On Friday? ↗
Elicio Therapeutics announced promising preliminary data from the AMPLIFY-7P Phase 1a study of ELI-002 7P, showing extended median disease-free survival in patients with mKRAS-driven solid tumors. 
Via Benzinga
News headline image
Elicio Therapeutics Announces Pricing of $11.5 Million Underwritten Public Offering
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Why Is Elicio Therapeutics (ELTX) Stock Down 36% Today? ↗
Elicio Therapeutics stock is down on Friday after the company announced a proposed public offering for shares of ELTX this morning. 
Via InvestorPlace
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗
Pre-market stock movers are a hot topic on Friday and we're breaking down all of the latest news sending shares higher and lower! 
Via InvestorPlace
News headline image
Elicio Therapeutics Announces Proposed Public Offering
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics Announces Preliminary Disease-Free Survival analysis from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P
ELI-002 7P administered as a monotherapy at the Phase 2 dose shows preliminary encouraging Disease-Free Survival data in pancreatic ductal adenocarcinoma 
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics Unveils Promising Phase 1a Data For ELI-002 7P In mKRAS Tumors
Elicio Therapeutics Unveils Promising Phase 1a Data For ELI-002 7P In mKRAS Tumors 
Via News Direct
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
ELTX Stock Earnings: Elicio Therapeutics Beats EPS for Q1 2024 ↗
ELTX stock results show that Elicio Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Elicio Therapeutics (NASDAQ: ELTX) Makes Strides In Growing Cancer Vaccination Industry
Elicio Therapeutics (NASDAQ: ELTX) Makes Strides In Growing Cancer Vaccination Industry 
Via News Direct
< Previous 1 2 3 4 5 Next >